Stauntoside B inhibits macrophage activation by inhibiting NF-κB and ERK MAPK signalling

Pharmacol Res. 2016 Sep:111:303-315. doi: 10.1016/j.phrs.2016.06.022. Epub 2016 Jun 22.

Abstract

Inflammation is a defensive reaction of body to resist foreign invasion. However, it has been demonstrated that excessive and continuous inflammatory responses contribute to various inflammatory diseases, including rheumatoid arthritis. Nuclear factor-κB (NF-κB) regulates the expression of an array of inflammatory mediators, cytokines and chemokine genes in activated macrophages. Therefore, NF-κB has become an attractive drug target for controlling inflammation. In this study, stauntoside B, a C21 steroidal glycosides compound isolated from a Chinese medicine Cynanchi Stauntonii, was for the first time found to suppress macrophage activation induced by lipopolysaccharide (LPS) in RAW264.7 cells and rat primary peritoneal macrophages and could be a potent NF-κB inhibitor. The results showed that stauntoside B significantly reduced the release of inflammatory mediators in activated RAW264.7 cells and rat peritoneal macrophages, including nitric oxide (NO) and prostaglandin E2 (PGE2). The mRNA expressions of pro-inflammatory mediators and cytokines, including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), microsomal prostaglandin synthetase-1 (mPGES-1), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) as well as the production of TNF-α and IL-6 were also inhibited by stauntoside B. Mechanistic investigation implies that the anti-inflammatory activity of stauntoside B could result from the suppression of LPS-induced IKKα/β activation, IκBα phosphorylation, p65 (ser536) NF-κB phosphorylation, and ERK MAPK activation by stauntoside B treatment in activated macrophages. Meanwhile, stauntoside B could induce apoptosis in LPS-activated macrophages. The current study suggests stauntoside B being a valuable candidate drug for the treatment of inflammatory diseases, especially for NF-κB activation associated inflammatory diseases.

Keywords: Anti-inflammatory activity; Cynanchi stauntonii; Lipopolysaccharide; MAPK; NF-κB; Stauntoside B; Stauntoside B (PubChem CID: 101010462).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Apoptosis / drug effects
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases / metabolism*
  • Inflammation / enzymology
  • Inflammation / genetics
  • Inflammation / prevention & control*
  • Inflammation Mediators / metabolism
  • Lipopolysaccharides / pharmacology
  • Macrophage Activation / drug effects*
  • Macrophages, Peritoneal / drug effects*
  • Macrophages, Peritoneal / enzymology
  • Mice
  • NF-kappa B / metabolism*
  • Phosphorylation
  • RAW 264.7 Cells
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rats, Sprague-Dawley
  • Saponins / pharmacology*
  • Signal Transduction / drug effects*
  • Steroids / pharmacology*

Substances

  • Anti-Inflammatory Agents
  • Inflammation Mediators
  • Lipopolysaccharides
  • NF-kappa B
  • RNA, Messenger
  • Saponins
  • Steroids
  • stauntoside B
  • Extracellular Signal-Regulated MAP Kinases